Cargando…

Optimal use of SGLT2 inhibitors in diabetic kidney transplant recipients

Sodium-glucose cotransporter 2 inhibitor (SGLT2i), a glucosuric agent initially approved for use as an antidiabetic agent, was unexpectedly found to confer cardio-and reno-protective effects in individuals with or without type 2 diabetes mellitus. Despite mounting evidence suggesting that SGLT2i pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Pham, Phuong-Thu T., Pham, Phuong-Chi T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10479656/
https://www.ncbi.nlm.nih.gov/pubmed/37674999
http://dx.doi.org/10.3389/fneph.2022.1014241

Ejemplares similares